Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Net Cash Flow (2017 - 2025)

Historic Net Cash Flow for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to $42.7 million.

  • Dianthus Therapeutics' Net Cash Flow rose 11522.57% to $42.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.3 million, marking a year-over-year increase of 11802.47%. This contributed to the annual value of -$109.4 million for FY2024, which is 19350.5% down from last year.
  • As of Q3 2025, Dianthus Therapeutics' Net Cash Flow stood at $42.7 million, which was up 11522.57% from $3.1 million recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' Net Cash Flow ranged from a high of $197.4 million in Q1 2024 and a low of -$280.3 million during Q3 2024
  • Its 4-year average for Net Cash Flow is $3.2 million, with a median of -$10.9 million in 2024.
  • Data for Dianthus Therapeutics' Net Cash Flow shows a peak YoY increase of 241559.83% (in 2024) and a maximum YoY decrease of 33972.14% (in 2024) over the last 5 years.
  • Quarter analysis of 4 years shows Dianthus Therapeutics' Net Cash Flow stood at -$21.5 million in 2022, then decreased by 15.99% to -$25.0 million in 2023, then soared by 56.41% to -$10.9 million in 2024, then soared by 492.38% to $42.7 million in 2025.
  • Its Net Cash Flow stands at $42.7 million for Q3 2025, versus $3.1 million for Q2 2025 and -$12.7 million for Q1 2025.